| Similar Articles |
|---|
 |
Reason
Aug/Sep 2001
Jacob Sullum |
Bad Timing "The Drug War Worked Once. It Can Again." So read the headline above William J. Bennett's May 15 defense of drug czar nominee John Walters in The Wall Street Journal...   |
Salon.com
May 17, 2001
Arianna Huffington |
Bush's drug two-faced drug war The president claims treatment is the best way to lower the demand for drugs. So why is his new drug czar so obsessed with punishment and prisons? |
Reason
Aug/Sep 2009
Ryan Grim |
The Drug Czar's High Math How phony statistics about cocaine prices hide the truth about the war on drugs. |
Reason
September 2005
Jacob Sullum |
Data: Pot Bust If you have any lingering doubts about the political establishment's hypocrisy when it comes to drugs, consider this: Marijuana arrests reached an all-time high during the administration of the first acknowledged pot smoker to occupy the White House. |
Reason
December 2001
Jacob Sullum |
Drugs and Thugs The U.S. Subsidy for Terrorists: "going after the illegal drug trade" is what allows terrorists to fund their operations with profits inflated by prohibition... |
Reason
April 2006
Jacob Sullum |
Blow in the Wind Despite reports to the contrary, the dramatic increase in interdiction has not had a noticeable impact on cocaine use. In a national survey, the number of past-month cocaine users was almost exactly the same in 2004 as it was in 2002. |
Salon.com
February 22, 2000
Michael Massing |
The elephant in the room Presidential candidates are silent on the failure of the U.S. war on drugs. |
Salon.com
April 24, 2001
Jake Tapper |
Virtually NORML Gov. Gary Johnson comes to Washington hoping to find converts to his anti-drug war crusade. He leaves one frustrated man... |
Reason
March 2003
Jacob Sullum |
High Road Is marijuana a "gateway"? |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
Reason
August 2003
Julian Sanchez |
Bad Ad The Office of National Drug Control Policy once occupied itself with protecting Americans from the total ruin that follows inexorably from that first puff on a joint. Its new mission is apparently to protect us (and, coincidentally, its budget) from Americans who question its policy. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
Reason
March 2003
Jacob Sullum |
Safety Hook The politics of "drugged driving" |
Reason
May 2003
Sara Rimensnyder |
Cosmetic Surgery Public dissatisfaction with the war on drugs is mounting, putting federal warriors under increasing pressure to cut an enforcement and treatment budget that has ballooned. But rather than actually spend less, the administration hopes to rely on some Enron-style creative bookkeeping. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
January 21, 2011
Brian Orelli |
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. |
Salon.com
July 27, 2000
Daniel Forbes |
Fighting "Cheech & Chong" medicine Did the White House drug office go too far in trying to stop the spread of medical marijuana initiatives? |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Salon.com
May 12, 2001
Katharine Mieszkowski |
What has Barry McCaffrey been smoking? The former drug czar goes dot-com with an Internet company that charges $1,200 for online drug treatment... |
The Motley Fool
March 30, 2011
Sean Williams |
China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
Salon.com
August 30, 2000
Arthur Allen |
Portrait of a drug czar Gen. Barry McCaffrey drives his government office like a lockstep battalion, but some contend his ruthless schedule and egomaniacal ways are only hurting his effort to bring sanity to America's drug policy. |
Salon.com
June 30, 2001
Daniel Forbes |
The quiet death of prime-time propaganda With no fanfare, the White House drug office pulls the plug on its controversial program to pay TV networks for putting anti-drug messages in popular shows... |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
April 7, 2011
Brian Orelli |
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market. |
Salon.com
March 12, 2002
Janelle Brown |
Saying no to propaganda Critics say the government's new anti-drug campaign is reactionary and moralistic. Worse, it may not even work... |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
January 28, 2011
Alan Oscroft |
AstraZeneca to Double Buybacks Regulatory setbacks have hit the drug firm's profits, but things look pretty resilient overall. |
Salon.com
October 20, 2000
Arianna Huffington |
Bye-bye, Barry McCaffrey Another drug czar leaves a failed tenure in office, declaring victory with a mess of skewed statistics... |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
March 31, 2010
Brian Orelli |
When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies. |
The Motley Fool
August 10, 2010
Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. |
Salon.com
May 24, 2001
Eric Boehlert |
Prime-time hypocrisy Barbara Walters helped ruin television news. So how did she get to be a martyr for journalistic credibility? |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
